PANAJI:
After being flagged a few months ago for defects, the USFDA has given its all clear to the Goa plant of Pharma major Cipla the company has announced.
It said, the Goa plant has been classified as Voluntary Action Indicated (VAI) after an inspection by a USFDA team thus enabling it to launch generic products manufactured here in the US markets.
"The United States Food and Drug Administration (USFDA) vide communication dated Wednesday, 30th October 2024 (8:28 p.m. IST) has classified the above-referred inspection as Voluntary Action Indicated (VAI)," the company's statutory filings to the stock exchange said.
The USFDA inspection was held at the Goa facility in June.
